SURMOUNT-1 Trial (New England Journal of Medicine, 2022) Randomized, double-blind, placebo-controlled 2,539 participants 72 weeks NCT04184622 Tirzepatide 5 mg -16.0% Mean body weight reduction Tirzepatide 10 mg -21.4% Mean body weight reduction Tirzepatide 15 mg -22.5% Mean body weight reduction Placebo group: -2.4% All results statistically significant (p 27 with Comorbidities Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss
Place your semaglutide inside immediately upon arrival
In wild-type mice, SFN treatment led to a decrease in the expression of Il17a and Il23a in psoriatic mouse skin compared to the IMQ group
But peptide stability is the limiting factor, not microbial risk
Maintaining adequate hydration is essential for patients taking semaglutide, particularly during the initial weeks of treatment when gastrointestinal side effects are most pronounced
Gizmodo: So what were the major takeaways